Skip to main content

Table 3 Univariate and multivariate analyses for the overall survival

From: Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance

  Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age# ≤30 NA§   NA§  
  31-40 1 (reference)   1 (reference)  
  41-50 0.88 (0.43–1.81) 0.721 0.64 (0.25–1.62) 0.343
  51-60 0.67 (0.31–1.47) 0.318 0.83 (0.32–2.15) 0.705
  61-70 1.17 (0.52–2.66) 0.704 0.96 (0.30–3.08) 0.949
  ≥71 0.51 (0.11–2.29) 0.376 0.52 (0.06–4.73) 0.564
Alcohol# No 1 (reference)   1 (reference)  
  Yes 1.03 (0.62–1.74) 0.899 1.07 (0.54–2.11) 0.842
Smoking# No 1 (reference)   1 (reference)  
  Yes 1.44 (0.71–2.93) 0.315 1.98 (0.79–4.97) 0.145
Betel nut# No 1 (reference)   1 (reference)  
  Yes 1.64 (0.83–3.26) 0.156 1.00 (0.42–2.37) 0.999
TNM staging# 1 1 (reference)   1 (reference)  
  2 1.18 (0.50–2.78) 0.703 0.76 (0.26–2.23) 0.618
  3 2.35 (0.95–5.86) 0.066 2.16 (0.78–6.02) 0.140
  4 4.21 (2.12–8.40) <0.001 3.53 (1.41–8.81) 0.007
EGFR Negative 1 (reference)    
  Positive 1.19 (0.70–2.02) 0.516 NA  
EGFR GCN Non-amplified 1 (reference)    
  Amplified 0.94 (0.57–1.57) 0.822 NA  
EGFRvIII# Low 1 (reference)    
  High 2.27 (1.36–3.79) 0.002 1.98 (1.01–3.87) 0.046
PTEN Negative 1 (reference)    
  Positive 1.26 (0.77–2.08) 0.359 NA  
pAKT# Negative 1 (reference)    
  Positive 2.51 (1.00–6.27) 0.050 2.67 (1.01–7.07) 0.049
  1. CI confidence interval, HR hazard ratio, NA not assessed.
  2. #Factors included in multivariate analysis.
  3. §Not assessed because the patient number was too small.